Respiratory Infections News

The Pfizer-BioNTech COVID-19 vaccine elicited “relatively lower” antibody levels in adults aged 50 years or older than in adults aged younger than 50 years, researchers reported in JAMA Network Open.

CDC Director Rochelle P. Walensky, MD, MPH, issued a statement late Thursday night endorsing her vaccine advisory committee’s recommendations — made earlier in the day — on which Americans should be eligible for COVID-19 booster shots.

A WHO guideline panel has updated recommendations for monoclonal antibody treatment in its “living” guide on drugs for COVID-19. The guidelines are published in The BMJ.

According to the CDC, manufacturers expect to deliver 188 million to 200 million doses of influenza vaccine in the United States this year.

I began my training at the beginning of the HIV pandemic. I still remember a lecture during my second year of medical school in which a young man told us that his friends were dying of a new disease called gay-related immunodeficiency disease, subsequently known as AIDS.

Additional doses of COVID-19 vaccine became available to people in the United States around 8 months after the first vaccine was authorized by the FDA.

The FDA has authorized booster doses of the Pfizer-BioNTech COVID-19 vaccine for people at high risk from the disease.

Hematopoietic stem cell transplant recipients responded well to the Pfizer-BioNTech COVID-19 vaccine in a single-center study, with 83% having an antibody response after two doses, researchers reported in JAMA Network Open.

Critically ill patients who required mechanical ventilation and received the probiotic Lactobacillus rhamnosus GG were as likely to develop ventilator-associated pneumonia as those who received placebo, a randomized clinical trial showed.

A second dose of Johnson & Johnson’s COVID-19 vaccine given 2 months after the initial shot boosted protection to 94% among people enrolled in a phase 3 trial in the United States, the company said Tuesday.